Vertex Pharmaceuticals develops small-molecule drugs for cystic fibrosis and other serious diseases. Its therapies target the underlying genetic defect in cystic fibrosis and have expanded treatment eligibility for patients globally. The company focuses on precision medicines and maintains an active pipeline in additional therapeutic areas.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 2,964.7 | — | 1,032.9 | — |
| Q3 2025 | 3,076.4 | — | 1,082.9 | -4.2% |
| Q4 2025 | 3,190 | — | 1,191.1 | 16.2% |
| Q1 2026 | 2,986.9 | — | 1,031.4 | -1.1% |
| Q2 2026 | 3,333.9 | 12.4% | 1,099.8 | 6.5% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Intuitive Surgical, Inc. (ISRG), Fortinet, Inc. (FTNT), Starbucks Corporation (SBUX), PDD Holdings Inc. (PDD), Adobe Inc. (ADBE), Automatic Data Processing, Inc. (ADP)